Cart
sales@molnova.com
Riamilovir
CAS No. 123606-06-4
Riamilovir( Triazavirin | 7-methylsulfanyl-3-nitro-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one )
Catalog No. M23411 CAS No. 123606-06-4
Riamilovir is a broad-spectrum antiviral drug candidate.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 92 | In Stock |
|
| 5MG | 129 | In Stock |
|
| 10MG | 222 | In Stock |
|
| 25MG | 389 | In Stock |
|
| 50MG | 575 | In Stock |
|
| 100MG | 801 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRiamilovir
-
NoteResearch use only, not for human use.
-
Brief DescriptionRiamilovir is a broad-spectrum antiviral drug candidate.
-
DescriptionRiamilovir is a broad-spectrum antiviral drug candidate.
-
In Vitro——
-
In Vivo——
-
SynonymsTriazavirin | 7-methylsulfanyl-3-nitro-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one
-
PathwayImmunology/Inflammation
-
TargetAntiviral
-
RecptorAntiviral
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number123606-06-4
-
Formula Weight228.19
-
Molecular FormulaC5H4N6O3S?
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCSC1=NC2=NN=C(C(=O)N2N1)[N+](=O)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Shahab S , Sheikhi M . Triazavirin - Potential Inhibitor for 2019-nCoV Coronavirus M Protease: A DFT Study[J]. Current Molecular Medicine, 2020.
molnova catalog
related products
-
Nepasaikosaponin K
Nepasaikosaponin K is a small molecule compound isolated from Chaikosaponin root with anti-influenza and antiviral activity and can be used in the study of viral infections.
-
YM-53403
YM-53403 is an antiviral activity that effectively inhibits the replication of RSV strains belonging to subgroup A and subgroup B. It can be used to treat respiratory syncytial virus infections.
-
LCC-12 FA
LCC-12 FA is a dimer composed of metformin that induces a decrease in the NAD(H) pool by targeting mitochondrial copper(ii).
